It has been established that patients with advanced NSCLC with the exon 21 L858R mutation generally do not derive as much benefit from TKI monotherapy compared to patients with exon 19 deletion.16 While TKI combined with chemotherapy has been suggested to improve PFS and ORR compared with TKI monotherapy,17 this combination is considered a treatment option for advanced EGFR-mutated NSCLC in the real world. This evidence concerns the gene EGFR and non-small cell lung carcinoma.